Minimale Resterkrankung (MRD) bei Krebs
Minimale Resterkrankung (MRD) bei Krebs (Teil I) Einleitung Im Bereich der Krebsbehandlung ist die frühe und genaue Diagnose...
About Us
- Home
- About Us
Who we are
LIQOMICS is an academic spin-off from Cologne, Germany, focused on advancing liquid biopsy technology for tumor diagnostics. We aim to make our liquid biopsy tests for genotyping and disease monitoring accessible to cancer patients worldwide. Our Vista family of products are ctDNA sequencing tests developed for exploratory genotyping in cancer patients and for detecting minimal residual disease (MRD) in follow-up samples. The tests cover the entire process from cell-free DNA (cfDNA) extraction and quality control to sequencing, target enrichment, and analysis with our in-house pipeline.
Highly sensitive minimal residual disease (MRD) detection
The Liqomics MRD test is a crucial tool for the early detection of low level MRD in cancer patients. With our proprietary workflow and bioinformatics we detect cancer with higher sensitivity than others. This can enable an earlier intervention in case of a relapse and hence an improved disease outcome for the patients.
Some key statistics of our assay
Sensitivity for Genotyping (SNPs / InDels) > 93%
Specificity for Genotyping (SNPs / InDels) > 99.999%
Sensitivity for MRD detection at MRD level > 10-5 > 88%
Specificity for MRD detection at MRD level > 10-5 > 99%
Limit of Detection for MRD ~ 5 x 10-6
Learn more about our assay
Our assay uses tumor mutations that we identify and track in blood to inform on the genetic drivers of a tumor and to quantify minimal residual disease (MRD)
Awards
Certifications & Standards
We work in conformity with the RiliBÄK guidelines of the German Medical Association
Certification Process Ongoing
In clinical trials we work in conformity with ICH-GCP (Good Clinical Practice)
You will be able to find our team here soon!
Our Team
How We Work
Partner with us
We are always on the lookout for collaborators.
Academic research, start-up or pharmaceutical industry. If you are excited about blood-based cancer genomics or highly sensitive minimal residual disease assessment across cancers we should start a conversation.
Get in contact with us and let us explore how we can team up.
Lates News & Articles
Fragmentomics by Liqomics
Exciting News: Fragmentomics by Liqomics We are thrilled to announce that our project, Fragmentomics by LIQOMICS, has been...
Zirkulierende Tumor-DNA (ctDNA)
Die Zukunft der Krebsdiagnostik: Zirkulierende Tumor-DNA (ctDNA) (Teil II) In unserem letzten Artikel haben wir die Grundlagen der...
- Sensitivity for Genotyping (SNPs / InDels) > 93%
- Specificity for Genotyping (SNPs / InDels) > 99.999%
- Sensitivity for MRD detection at MRD level of > 10-5 > 88%
- Specificity for MRD detection at MRD level of > 10-5 > 99%
- Limit of Detection for MRD ~5 x 10-6